Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

The yin and yang of interleukin-2-mediated immunotherapy.

Bluestone JA.

N Engl J Med. 2011 Dec 1;365(22):2129-31. doi: 10.1056/NEJMe1110900. No abstract available.

PMID:
22129258
2.

A delicate balance: tweaking IL-2 immunotherapy.

[No authors listed]

Nat Med. 2012 Feb 6;18(2):208-9. doi: 10.1038/nm0212-208. No abstract available.

PMID:
22310686
3.

Low-dose interleukin-2 and HCV-induced vasculitis.

Oo YH, Mutimer D, Adams DH.

N Engl J Med. 2012 Apr 5;366(14):1353-4; author reply 1354. doi: 10.1056/NEJMc1200978#SA1. No abstract available.

PMID:
22475612
4.

Regulatory T cells in graft-versus-host disease.

Margolick JB.

N Engl J Med. 2012 Mar 8;366(10):962-3; author reply 963. doi: 10.1056/NEJMc1115197#SA2. No abstract available.

PMID:
22397663
5.

Regulatory T cells in graft-versus-host disease.

Masuda S.

N Engl J Med. 2012 Mar 8;366(10):962; author reply 963. doi: 10.1056/NEJMc1115197#SA1. No abstract available.

PMID:
22397662
6.

[Exploring regulatory T cell-based therapy for refractory graft-versus-host disease].

Matsuoka K.

Rinsho Ketsueki. 2014 Jun;55(6):670-81. Japanese. No abstract available.

PMID:
24975336
8.
9.

Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4(+)CD25 (high)CD127 (low/-) regulatory T cells.

Ukena SN, Grosse J, Mischak-Weissinger E, Buchholz S, Stadler M, Ganser A, Franzke A.

Ann Hematol. 2011 Feb;90(2):213-8. doi: 10.1007/s00277-010-1068-0. Epub 2010 Sep 22.

PMID:
20859740
10.

Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease.

Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK.

J Exp Med. 2006 Dec 25;203(13):2785-91. Epub 2006 Nov 27.

11.

CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.

Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cheraï M, Beaumont JL, Azar N, Dhedin N, Sirvent A, Buzyn A, Rubio MT, Vigouroux S, Montagne O, Bories D, Roudot-Thoraval F, Vernant JP, Cordonnier C, Klatzmann D, Cohen JL.

Sci Transl Med. 2010 Jul 21;2(41):41ra52. doi: 10.1126/scitranslmed.3001302.

12.
13.

[Could we cure type 1 diabetes by stimulating T(reg)?].

Grinberg-Bleyer Y, Baeyens A, Piaggio E, Salomon BL.

Med Sci (Paris). 2011 May;27(5):471-2. doi: 10.1051/medsci/2011275008. Epub 2011 May 25. French. No abstract available.

14.

Old cancer drug gets fresh look.

Ledford H.

Nature. 2014 May 29;509(7502):541-2. doi: 10.1038/509541a. No abstract available.

PMID:
24870520
15.

Treatment of hepatitis C virus-related systemic vasculitis.

Cacoub P, Saadoun D, Sene D, Limal N, Piette JC.

J Rheumatol. 2005 Nov;32(11):2078-82. No abstract available.

16.

Modulation of graft-versus-host disease: role of regulatory T lymphocytes.

Hess AD.

Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 2):13-21. Review.

17.

The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease.

Cohen JL, Boyer O.

Curr Opin Immunol. 2006 Oct;18(5):580-5. Epub 2006 Aug 1. Review.

PMID:
16879951
18.

Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease.

Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, Renoldi G, Parma M, Balduzzi A, Perseghin P, Biondi A.

Transplantation. 2007 Jul 15;84(1):31-9.

PMID:
17627234
19.

[Control of immune responses by regulatory dendritic cells].

Sato K.

Rinsho Ketsueki. 2011 Jul;52(7):514-20. Review. Japanese. No abstract available.

PMID:
21821983
20.

Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.

Coenen JJ, Koenen HJ, van Rijssen E, Kasran A, Boon L, Hilbrands LB, Joosten I.

Bone Marrow Transplant. 2007 May;39(9):537-45. Epub 2007 Mar 12.

PMID:
17351648

Supplemental Content

Support Center